Recent data from the SWEDEHEART registry has shown a marked increase in the use of SGLT-2 inhibitors and GLP-1RA in recent years, with more than 60% of post-MI patients being treated with either or both classes of drugs in 2023 [4]. The gene discussed is SLC5A2; the disease is myocardial infarction.